Global benchmarks for innovation and quality are being set by Australia's medical manufacturing sector.
Despite the difficulties brought on by the worldwide coronavirus pandemic, Australia's multibillion-dollar pharmaceutical industry has been expanding consistently over the past ten years.
With the biggest economies in Asia, namely China, Japan, and Korea, as well as the rapidly developing nations of Southeast Asia, Australia enjoy free trade agreements. Additionally, the nation enjoys solid ties with the top research and academic institutions in Asia, which creates opportunities for joint R&D projects.
Let’s take a look at some of the best 5 ASX pharmaceutical companies’ in Australia. These are as follows:
Note: The market cap and the share price of the selected ASX companies below are mentioned as of 29 January 2024.
Clarity Pharmaceuticals Limited (ASX: CU6)
Market cap: $621.94 million
CMP: $2.37
The company procured Cu SAR-bisPSMA for Clarity's pivotal Phase III clinical trials by entering into a Master Service Agreement and a Clinical Supply Agreement with PETNET Solutions Inc.
The company's income and revenues increased from $6.5 million in 2022 to $11.6 million in 2023, a 77.9% increase. As it achieved important milestones in clinical trials, Clarity saw noteworthy advancements in the development of three of its core products: SAR bisPSMA, SAR-Bombesin, and SARTATE. It is anticipated that these benchmarks will enable the organization to fulfill its objective of creating the upcoming line of radiopharmaceutical products.
Mayne Pharma Group Limited (ASX: MYX)
Market cap: $450.05 million
CMP: $5.29
In FY2024, the company anticipates launching new products and seeing growth in the dermatology segment. Another important strategic area in the international segment will be the new strategic investments and manufacturing revenue stream. In general, positive contribution margins are anticipated in each of the three segments. The company's main goal is to produce positive cash generation and EBITDA in FY2024. An additional NEXTSTELLIS U.S. patent was reported by Mayne Pharma Group Limited. This new patent will strengthen the "NEXTSTELLIS" portfolio and is another one that is listed in the Orange Book.
Botanix Pharmaceuticals Limited (ASX: BOT)
Market cap: $257.97 million
CMP: $0.165
With FDA approval of Sofpironium Bromide (SB) for primary axillary hyperhidrosis anticipated by September 2023, the company has been gradually moving in that direction. Agreements with important pharmacy and telemedicine platform partners are still pending, but the company has been continuously reviewing its plans for SB's commercial launch. These agreements should be finalized soon. Additionally, the company has actively sought out key personnel to join the team. Before the end of August, the company plans to announce these additions and changes to functions. It has been working nonstop to get the proposed brand name approved and to draft agreements with important commercial partners about launch supplies, payers, and distribution, which will be finalized after SB approval.
Arovella Therapeutics Limited (ASX: ALA)
Market cap: $119.39 million
CMP: $0.13
Arovella holds strong revenue-generating prospects in the long term given the development and technological edge its treatment stands to provide, both from a commercial perspective as well as from an efficacy point of view for the user. The company’s cell therapy platform further has several key advantages over existing CAR-T treatments, encouraging the disruptive potential of Arovella. The company had expected preliminary in vivo data for the study to be available before the end of 2023, but the availability of this data has been delayed by Arovella’s contract research provider due to technical challenges with the pilot study.
Argenica Therapeutics Limited (ASX: AGN)
Market cap: $61.47 million
CMP: $0.62
The recent studies on ARG-007 highlight its ability to significantly reduce abnormal tau uptake and inhibit tau aggregation, marking a potential breakthrough in neurodegenerative disease treatment. Additionally, Argenica has received ethics approval for a Phase 2 clinical trial in acute ischaemic stroke patients, with preparations underway across ten Australian hospitals for patient recruitment starting in Q1 CY 2024. Simultaneously, ongoing animal studies are being conducted by Argenica to validate ARG-007's efficacy in Alzheimer's disease, with updates on milestones expected as the research progresses.
Reference: *All Data has been sourced from Company announcements and Refinitiv, Thomson Reuters
Frequently Asked Questions (F.A.Q)
What are the best 5 ASX pharmaceutical companies in Australia for 2024?
• Clarity Pharmaceuticals Limited (ASX:CU6)
• Argenica Therapeutics Limited (ASX: AGN)
• Arovella Therapeutics Limited (ASX:ALA)
• Botanix Pharmaceuticals Limited (ASX:BOT)
• Clarity Pharmaceuticals Limited (ASX:CU6)
What are the fundamental prospects of Mayne Pharma Group Limited (ASX: MYX)?
The company is trying to boost efficiency and profitability while also managing its capital well and increasing leverage on fixed assets. As of 31 October 2023, the company's cash balance was $163.9 million. The company's recent "buyback" is a sign that its fundamentals are becoming even more solid. Relentlessly pursuing the objective of supervising the divestment of Metrics Contract Services, the company fulfilled its debt facility obligation of $361 million and distributed a fully franked dividend of $47 million to shareholders. All in all, the business gains a more optimistic outlook for the future.
How will pharma be impacted by global trends?
This shift is probably going to result in new supply chains, distinct product life cycles, and increased technological fragmentation. Pharma has been impacted by both industry-specific and global trends, including pressures on the supply chain.
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.